Clinical trial
A Multicenter Clinical Study on the Safety and Efficacy of KSVCBD Injection in the Treatment of Multiple Myeloma With Positive Expression of CD19 and/or BCMA
NCT07620275 is registered in ClinicalTrials.gov with Chinese PLA General Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter Clinical Study on the Safety and Efficacy of KSVCBD Injection in the Treatment of Multiple Myeloma With Positive Expression of CD19 and/or BCMA
- Lead sponsor
- Chinese PLA General Hospital
- Phase
- Phase 1
- Overall status
- Recruiting
- Start date
- September 3, 2026
- Completion date
- March 15, 2029
- Enrollment
- 9 (estimated)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.